Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke

Abstract

The introduction of direct oral anticoagulants (DOA) in the early stage of cerebral infarction after thrombolysis may reduce the recurrence rate but raises safety concern. We sought to study the feasibility and safety of the introduction of rivaroxaban or dabigatran in this context. Thirty-four consecutive patients admitted for ischemic stroke related to non-valvular atrial fibrillation in whom DOA were given within the first two weeks following intravenous rt-PA were studied. A clinical and radiological monitoring protocol was established to ensure the safety of the prescription. None of the patients experienced symptomatic hemorrhagic transformation or a symptomatic recurrent ischemic event after early rivaroxaban or dabigatran introduction.

Keywords: Accident ischémique cérébral; Acute stroke; Anticoagulant direct; Anticoagulants; Atrial fibrillation; Dabigatran; Dabigatran etexilate; Fibrillation atriale; Rivaroxaban; Thrombolysis.